## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 9.9% in upper entry zone (4.0-10.0%), top 6% cross-sectional ranking. Short-term MRS_5 (6.1%) confirms momentum alignment. Strong momentum (+8.2% 5-day acceleration). Outperforming sector by 8.5%. Caution: overbought RSI (74).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($51.53)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 10, Bearish: 0)

**1. Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025**
- Source: ts2.tech | 20251216T115801 | Bullish | Relevance: 100%
- Bristol-Myers Squibb (BMY) stock rose by 3.6% on December 16, 2025, driven by a Bank of America upgrade to Buy with a $61 price target, an increased quarterly dividend of $0.63 per share, and significant pipeline developments. Key catalysts include recent FDA approvals, priority reviews for Opdivo, and upcoming data readouts for various programs in 2026, which signal a potential return to growth despite ongoing patent cliff concerns. These factors suggest increasing Wall Street confidence in Bristol-Myers Squibb's post-patent cliff transition strategy.

**2. Why Bristol-Myers Squibb (BMY) Stock Is Up Today**
- Source: TradingView â€” Track All Markets | 20251215T190746 | Bullish | Relevance: 100%
- Shares of Bristol Myers Squibb (BMY) rose 3.7% after BofA Securities upgraded the stock from "Neutral" to "Buy," citing the strength of its R&D pipeline and increasing its price target to $61. This follows a similar upgrade from Guggenheim and positive news including a dividend increase and FDA approval for Breyanzi. Despite recent gains, BMY is still down 4.3% year-to-date and trading below its 52-week high, indicating potential investor opportunity.

**3. Why Bristol-Myers Squibb (BMY) Stock Is Up Today**
- Source: Markets Financial Content | 20251215T142500 | Bullish | Relevance: 100%
- Shares of Bristol-Myers Squibb (BMY) jumped 3.7% after BofA Securities upgraded the stock from "Neutral" to "Buy," citing a strong R&D pipeline and increasing its price target to $61. This positive sentiment was reinforced by a recent Guggenheim upgrade, a dividend increase, and FDA approval for the company's CAR T cell therapy, Breyanzi. Despite these gains, the stock remains down 4.3% year-to-date and 13.9% below its 52-week high.

**4. Shorepoint Capital Partners LLC Acquires Shares of 67,705 Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251216T122509 | Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC initiated a new position in Bristol Myers Squibb (NYSE:BMY) during the third quarter, acquiring 67,705 shares valued at approximately $3.05 million. This move aligns with increased institutional investment in BMY, with major players like Vanguard and Charles Schwab also boosting their stakes. The biopharmaceutical company recently surpassed quarterly earnings and revenue estimates and raised its quarterly dividend.

**5. Assessing Bristol Myers Squibb After 16% Rally and New Drug Approvals in 2025**
- Source: Simply Wall Street | 20251216T010754 | Bullish | Relevance: 100%
- Bristol-Myers Squibb (BMY) has seen a 16.4% rally over the last 30 days due to renewed investor interest in its pipeline and strategic deals. Despite still being down year-to-date, the stock currently appears undervalued according to Discounted Cash Flow and Price-to-Earnings analyses, with intrinsic values suggesting significant upside potential. However, differing "Narratives" highlight both bull and bear cases, emphasizing the importance of considering factors like new drug approvals, patent expirations, and cost savings programs.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- Momentum building: MRS_20 improving +8.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.5B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.1 |
| Current P/E | 8.3 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 1.7% to 9.9% (+8.2% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 at 6.1% confirms short-term momentum alignment. AM_20 at 9.6% shows strong absolute momentum above own 20MA. Outperforming sector by 8.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 74, risk of mean reversion. OFD pattern: +STN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 9.89% (CS: 94) | Strong |
| RSI_14 | 73.6 | Overbought |
| MACD Histogram | 0.29 | Bullish |
| vs SMA20 | 1.096x | Above |
| vs SMA50 | 1.158x | Above |
| vs SMA200 | 1.110x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $54.29
- **Stop Loss:** $51.53 (5.1% risk)
- **Target:** $58.43 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 434
- **Position Value:** $23,561.86
- **Portfolio %:** 23.56%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*